Robert Barrow

In a new chapter of the management quarrel between MindMed (NASDAQ: MNMD) executives and shareholder group FCM Holdings, the company has published an independent report by former senior FDA officials on its clinical and regulatory plan for proprietary LSD compound and lead drug candidate, MM-...

Clinical-stage biotech company Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) reported its financial results and updated on its programs pipeline of the third quarter ended September 30, 2022. For the period, total cash was equivalent to $154.5 million -compared to $133.5 million as of December 31,...

The clinical-stage biopharma company Mind Medicine -also known as MindMed (NASDAQ: MNMD), which recently made headlines regarding its stock, announced it will begin dosing patients within its Phase 2b trial on LSD compound, MM-120, for the treatment of Generalized Anxiety Disorder (GAD)....

MindMed (NASDAQ: MNMD), which recently received a letter on behalf of one of its shareholders calling for a new business strategy and offering a solution, reported its earnings for the quarter ended June 30, 2022. And the next day, it announced the appointment of two independent...

Mind Medicine Names New CEO Mind Medicine Inc. (NASDAQ: MNMD) (NEO: MMED) has hired Schond L. Greenway to oversee its finance department. Greenway comes to MindMed with over two decades of experience in investment banking, finance and corporate advisory, and investment analysis in the life sciences...

Mind Medicine Inc. (NASDAQ: MNMD), (NEO:MMED), a clinical stage bio-pharmaceutical company developing novel products to treat brain health disorders, appointed Schond L. Greenway as CFO. Greenway comes to MindMed with over 20 years of experience in investment banking, finance and corporate advisory...

With over ten years of experience in the pharmaceutical industry, Robert Barrow, CEO of Mind Medicine Inc. (NASDAQ: MNMD) is someone who certainly knows the ins and outs of the business. Barrow joined MindMed in January 2021 as Chief Development Officer (CDO) but was later appointed as CEO and...

Psychedelics-focused biopharma company Mind Medicine Inc. (NASDAQ: MNMD), (NEO:MMED), (DE:MMQ) confirmed Wednesday that all the company’s issued and outstanding multiple voting shares will undergo a mandatory conversion into subordinate voting shares in accordance with the company’s...

Media company Global Trac Solutions, Inc. (OTCP:PSYC) and authorities behind psychedelic news and information platform Psychedelic Spotlight, announced that Psychedelic Spotlight will host its first “CEO Roundtable” on Feb. 15. The event is scheduled to be streamed live on YouTube via...

MindMed (NASDAQ: MNMD), a drug development company in the psychedelics space, announced on Tuesday that the FDA has allowed an investigational new drug application for a Phase 2b trial on a proprietary LSD analog. Shares from the company peaked at $1.30 and closed the Tuesday trading session at $1....

Mind Medicine Inc (NASDAQ: MNMD) is trading higher Tuesday morning after the company announced the U.S. Food and Drug Administration (FDA) cleared its Investigational New Drug (IND) application, allowing its Phase 2b dose-optimization trial of MM-120 for the treatment of generalized anxiety...

Stephen Hurst Steps Down From MindMed's Board Of Directors Psychedelic-focused biotech company Mind Medicine Inc (NASDAQ: MNMD) announced on Friday that Stephen Hurst has resigned from his role as director of the company's board. Robert Barrow, CEO and director of the New...

On Tuesday, Mind Medicine Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) reported the completion of its Phase 1 clinical trial of 18-MC, the company’s non-hallucinogenic proprietary derivative of ibogaine, being developed for the treatment of indications linked to opioid use disorder. The...

MindMed Announces Management Shake-Ups Mind Medicine Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ), a psychedelic-based biotech company, announced Wednesday that Bradford Cross, its chief technology officer, has transitioned from his role. Robert Barrow, the company's CEO and director, thanked...

MindMed (NASDAQ: MNMD) (NEO: MMED), a clinical-stage biotech company that is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances, announced on Dec. 21 that the  Food and Drug Administration (FDA) has placed a clinical hold on its...